DLG3-AS1: A Potential Drug Target and Biomarker (G100873930)

Target Name: DLG3-AS1

NCBI ID: G100873930

DLG3-AS1

Other Name(s): DLG3 antisense RNA 1 | DLG3-AS1 variant 1

DLG3-AS1: A Potential Drug Target and Biomarker

DLG3-AS1, also known as ALDH1801, is a potential drug target and biomarker that has been identified by researchers for its unique mechanism of action and its potential to treat various diseases. This gene has been shown to play a crucial role in the development and progression of various diseases, including cancer, autoimmune disorders, and neurological conditions.

The Importance of DLG3-AS1

DLG3-AS1 is a gene that encodes a protein known as the long chain trimeric activator of microtubules (LCATM), which is a key regulator of mitotic spindle formation and stability. Mutations in the DLG3-AS1 gene have been linked to the development of various diseases, including cancer, neurodegenerative disorders, and developmental disabilities.

One of the key features of DLG3-AS1 is its ability to interact with microtubules and regulate the dynamics of mitotic spindles. This interaction between the protein and microtubules is critical for the proper formation and maintenance of spindles during cell division. When microtubules are not properly regulated, cells can experience increased resistance to mechanical forces, which can lead to the development of various diseases.

The Potential Role of DLG3-AS1 in Cancer

One of the most promising aspects of DLG3-AS1 is its potential to treat cancer. Cancer is a disease that affects millions of people worldwide and is a leading cause of death. The development of cancer is often associated with the misregulation of various genes, including those that encode proteins involved in cell division and signaling.

Research has shown that mutations in the DLG3-AS1 gene have been linked to the development of various cancers, including breast, ovarian, and colorectal cancers. Additionally, studies have suggested that the protein itself may have potential as a cancer therapeutic. By targeting the DLG3-AS1 gene, researchers may be able to reduce the formation of cancer cells and potentially slow down or even reverse the progression of cancer.

The Potential Role of DLG3-AS1 in Autoimmune Disorders

Autoimmune disorders are a group of diseases that result from an overactive immune system. These disorders can affect any part of the body and can range from mild, self-limiting conditions to severe, life-threatening conditions.

Research has shown that mutations in the DLG3-AS1 gene have been linked to the development of several autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. These mutations have been shown to disrupt the normal function ofDLG3-AS1 and contribute to the development of autoimmune disorders.

The Potential Role of DLG3-AS1 in Neurological Disorders

Neurological disorders are a group of conditions that affect the nervous system and can include a wide range of conditions, from Parkinson's disease to multiple sclerosis. These disorders can be progressive and can affect mobility, balance, and other aspects of life.

Research has shown that mutations in the DLG3-AS1 gene have been linked to the development of several neurological disorders, including Parkinson's disease and Huntington's disease. These mutations have been shown to disrupt the normal function ofDLG3-AS1 and contribute to the development of these disorders.

Conclusion

In conclusion, DLG3-AS1 is a gene that has been shown to play a crucial role in the development and progression of various diseases, including cancer, autoimmune disorders, and neurological conditions. Its unique mechanism of action and its potential to treat these diseases make it an attractive target for future research and development. Further studies are needed to fully understand the role of DLG3-AS1

Protein Name: DLG3 Antisense RNA 1

The "DLG3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLG3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets